|

131-I Apamistamab Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Iomab-B

Pipeline

Early 1: 1

Top Sponsors

  • Memorial Sloan Kettering Cancer Center1

Indications

  • HGBL1
  • DLBCL Activated B-Cell Type1
  • DLBCL Unclassifiable1
  • Dlbcl-Ci1
  • DLBCL Germinal Center B-Cell Type1

Basking Ridge, New Jersey1 trial

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.